QIAGEN N.V.
Venlo, The Netherlands

Interim Financial Report

June 30, 2013

(unaudited)

QIAGEN N.V.

CONDENSED FINANCIAL REPORT PERIOD ENDED JUNE 30, 2013

TABLE OF CONTENTS

QIAGEN N.V.

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(in thousands)

	Note	June 30, 2013	December 31, 2012
		(unaudited)	
Assets			
Current assets:			
Cash and cash equivalents		$ 300,317	$ 394,702
Current available-for-sale financial instruments		73,379	90,451
Trade accounts receivable		247,968	250,729
Income taxes receivable		41,966	39,150
Inventories	**(11)**	132,646	135,293
Prepaid expenses and other current assets		61,035	36,149
Total current assets		**857,311**	**946,474**
Non-current assets:			
Property, plant and equipment		366,386	377,623
Goodwill	**(6)**	1,816,496	1,783,913
Other intangible assets	**(6)**	881,971	946,602
Investments in associates	**(5)**	23,109	22,122
Non-current available-for-sale financial instruments	**(5)**	15,146	15,511
Deferred tax assets		7,994	8,238
Other non-current assets		28,157	21,047
Total non-current assets		**3,139,259**	**3,175,056**
Total assets		**$ 3,996,570**	**$ 4,121,530**

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V.

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(in thousands, except per share data)

	Note	June 30, 2013	December 31, 2012
		(unaudited)	
Liabilities and equity			
Current liabilities:			
Current financial debts	**(9)**	$ 727	$ 948
Trade and other accounts payable		43,467	51,311
Provisions		5,361	5,636
Income tax payable		41,414	14,879
Other current liabilities		213,522	189,983
Total current liabilities		**304,491**	**262,757**
Non-current liabilities:			
Non-current financial debts	**(9)**	845,629	841,685
Deferred tax liabilities		156,196	165,259
Other non-current liabilities		48,062	57,739
Total non-current liabilities		**1,049,887**	**1,064,683**
Equity:			
Common shares		2,808	2,769
Share premium		1,926,291	1,884,547
Retained earnings		826,684	883,655
Reserves		(24,126)	49,113
Treasury shares	**(12)**	(98,993)	(35,653)
Equity attributable to the owners of QIAGEN N.V.		**2,632,664**	**2,784,431**
Non-controlling interest		9,528	9,659
Total equity		**2,642,192**	**2,794,090**
Total liabilities and equity		**$ 3,996,570**	**$ 4,121,530**

Issued Shares		
Authorized common shares: 410,000, EUR 0.01 par value	239,411	236,487
Authorized preference shares: 450,000, EUR 0.01 par value	—	—
Authorized financing shares: 40,000, EUR 0.01 par value	—	—

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
(in thousands, except per share data)

	Note	Six months ended June 30, 2013	2012
		(unaudited)	
Net sales		**$ 618,788**	**$ 603,635**
Cost of sales		**(250,384)**	(211,590)
Gross profit		**368,404**	**392,045**
Operating expenses:			
Other operating income		**8,089**	98
Research and development expense		**(65,395)**	(60,692)
Sales and marketing expense		**(201,186)**	(187,484)
General and administrative, restructuring, integration and other expense	**(4)**	**(123,265)**	(66,682)
Other operating (expense)		**(9,687)**	(57)
Total operating expenses		**(391,444)**	**(314,817)**
(Loss) Income from operations		**(23,040)**	**77,228**
Financial income		**2,522**	2,388
Financial expense		**(19,866)**	(15,478)
Foreign currency (losses), net		**(930)**	(3,082)
Gain from investments in associates		**957**	537
Other (expense) income, net	**(5)**	**(3,444)**	1,733
(Loss) income before income taxes		**(43,801)**	**63,326**
Income tax expense		**(13,057)**	(4,218)
Net (loss) income		**$ (56,858)**	**$ 59,108**
- attributable to non-controlling interest		**$ 113**	$ 248
- attributable to the owners of QIAGEN N.V.		**$ (56,971)**	$ 58,860
Basic (loss) earnings per common share attributable to the owners of QIAGEN N.V.		**$ (0.24)**	$ 0.25
Diluted (loss) earnings per common share attributable to the owners of QIAGEN N.V.		**$ (0.24)**	$ 0.25
Weighted average shares outstanding (in thousands)			
Basic		**233,699**	**235,302**
Diluted		**233,699**	**237,265**

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands)

	Note	Six Months Ended June 30, 2013	2012
		(unaudited)	
Net (loss) income		**$ (56,858)**	**$ 59,108**
Other comprehensive income (loss) to be reclassified to profit or loss in subsequent periods:			
Gains on cash flow hedges, before tax	**(7)**	—	3,541
Reclassification adjustments on cash flow hedges, before tax	**(7)**	—	(2,978)
Cash flow hedges, before tax		—	563
Foreign currency translation adjustments, before tax		(71,305)	(7,716)
Other comprehensive loss, before tax		**(71,305)**	**(7,153)**
Income tax relating to components of other comprehensive loss		(1,716)	(343)
Total other comprehensive loss, after tax		(73,021)	(7,496)
Total comprehensive (loss) income		**$ (129,879)**	**$ 51,612**
- attributable to non-controlling interest		331	12
- attributable to the owners of QIAGEN N.V.		(130,210)	51,600

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

	Note	Six months ended June 30, 2013	2012
		(unaudited)	
Net (loss) income		$ (56,858)	$ 59,108
Adjustments to reconcile net (loss) income to net cash provided by operating activities net of effects of businesses acquired:			
Depreciation and amortization		101,731	99,712
Non-cash impairment of intangibles and other assets		57,167	—
Non-cash impacts from convertible notes		4,358	5,047
Gain on sale of property, plant and equipment		—	369
Deferred income taxes		(20,526)	(23,771)
Share based compensation	(15)	21,424	14,684
Other non-cash items		5,048	22,216
Net changes in other operating assets and liabilities:			
Accounts receivable		(2,599)	5,837
Inventories		(18,599)	(25,927)
Income tax receivables		(4,884)	(12,145)
Other assets		(20,515)	(4,577)
Accounts payable		(11,780)	126
Accrued and other liabilities		13,672	(33,212)
Income tax payables		37,305	70
Net cash provided by operating activities		**104,944**	**107,537**
Purchases of property, plant and equipment		(33,695)	(41,836)
Purchases of intangible assets		(15,663)	(5,121)
Capitalization of development expenses		(8,079)	(3,612)
Proceeds from sale of equipment		40	806
Sale of available-for-sale assets		15,859	—
Purchase of investments		(4,136)	(7,000)
Cash paid for acquisitions, net of cash acquired		(102,395)	(131,810)
Other investing activities		2,394	—
Net cash used in investing activities		**(145,675)**	**(188,573)**
Net proceeds from short-term debt		—	68,870
Repayment of long-term debt		(633)	(65)
Principal payments on finance leases		(2,010)	(2,000)
Proceeds from issuance of common shares		18,053	12,468
Purchase of treasury shares		(63,340)	—
Other financing activities		(616)	(4,928)
Net cash (used in) provided by financing activities		**(48,546)**	**74,345**
Effect of exchange rate changes on cash and cash equivalents		(5,108)	(198)
Net decrease in cash and cash equivalents		(94,385)	(6,889)
Cash and cash equivalents, beginning of period		394,702	221,598
Cash and cash equivalents, end of period		$ 300,317	$ 214,709

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(in thousands)

(unaudited)	Note	Common Shares		Share premium	Retained earnings	Cash flow hedge reserve	Foreign currency translation	Reserves	Treasury Shares		Equity attributable to the owners of QIAGEN N.V.	Non-controlling interest	Total equity
		Shares	Amount						Shares	Amount			
BALANCE AT JANUARY 1, 2012		234,221	$ 2,739	$1,842,648	$ 757,464	$ (762)	$ 21,228	$ 20,466	—	$ —	$ 2,623,317	$ 9,494	$ 2,632,811
Net income		—	—	—	58,860	—	—	—	—	—	58,860	248	59,108
Other comprehensive income		—	—	—	—	394	(7,654)	(7,260)	—	—	(7,260)	(236)	(7,496)
Total comprehensive income		—	—	—	58,860	394	(7,654)	(7,260)	—	—	51,600	12	51,612
Tax benefit of employee stock plans		—	—	3,138	—	—	—	—	—	—	3,138	—	3,138
Share-based payments		—	—	14,441	—	—	—	—	—	—	14,441	—	14,441
Employee stock plans		1,703	22	12,446	—	—	—	—	—	—	12,468	—	12,468
BALANCE AT JUNE 30, 2012		235,924	$ 2,761	$1,872,673	$ 816,324	$ (368)	$ 13,574	$ 13,206	—	$ —	$ 2,704,964	$ 9,506	$ 2,714,470
BALANCE AT JANUARY 1, 2013		**236,487**	**$ 2,769**	**$1,884,547**	**$ 883,655**	**$ —**	**$ 49,113**	**$ 49,113**	**(1,943)**	**$ (35,653)**	**$ 2,784,431**	**$ 9,659**	**$ 2,794,090**
Net (loss) income		—	—	—	**(56,971)**	—	—	—	—	—	**(56,971)**	**113**	**(56,858)**
Other comprehensive (loss) income		—	—	—	—	—	**(73,239)**	**(73,239)**	—	—	**(73,239)**	**218**	**(73,021)**
Total comprehensive (loss) income		—	—	—	**(56,971)**	—	**(73,239)**	**(73,239)**	—	—	**(130,210)**	**331**	**(129,879)**
Purchase of treasury shares	**(12)**	—	—	—	—	—	—	—	**(3,128)**	**(63,340)**	**(63,340)**	—	**(63,340)**
Tax benefit of employee stock plans		—	—	**2,306**	—	—	—	—	—	—	**2,306**	—	**2,306**
Share-based payments	**(15)**	—	—	**21,424**	—	—	—	—	—	—	**21,424**	—	**21,424**
Employee stock plans		**2,924**	**39**	**18,014**	—	—	—	—	—	—	**18,053**	—	**18,053**
Acquisition of Ipsogen S.A. shares from non-controlling interests	**(3)**	—	—	—	—	—	—	—	—	—	—	**(462)**	**(462)**
BALANCE AT JUNE 30, 2013		**239,411**	**$ 2,808**	**$1,926,291**	**$ 826,684**	**$ —**	**$ (24,126)**	**$ (24,126)**	**(5,071)**	**$ (98,993)**	**$ 2,632,664**	**$ 9,528**	**$ 2,642,192**

The accompanying notes are an integral part of these condensed consolidated financial statements.

QIAGEN N.V.

Selected explanatory notes to the condensed consolidated financial statements for the six months ended June 30, 2013 (unaudited)

1. Corporate Information

QIAGEN N.V. is a public limited liability company ('naamloze vennootschap') under Dutch law with a registered office at Spoorstraat 50, Venlo, The Netherlands. QIAGEN N.V. as the holding company and Subsidiaries ('the Company', 'Group', 'we' or 'QIAGEN') is a leading provider of innovative Sample and Assay Technologies. These technologies—consumable products such as sample and assay kits and automated instrumentation systems—empower customers to transform raw biological samples into valuable molecular information. We serve four major customer classes: Molecular Diagnostics laboratories; Applied Testing customers in fields such as forensics, veterinary diagnostics and food safety; Pharmaceutical research and development groups, and Academic researchers. We market our products in more than 100 countries.

2. Basis of Presentation and Accounting Policies

The accompanying condensed consolidated financial statements were prepared in accordance with International Financial Reporting standards (IFRS) for interim financial information under International Accounting Standards (IAS) 34 *Interim Financial Reporting* as endorsed by the European Union (EU). The consolidated financial statements have been prepared on a historical cost basis, except for derivative financial instruments, contingent consideration and available-for-sale financial instruments that have been measured at fair value. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary for a fair presentation have been included. All amounts are presented in U.S. dollars rounded to the nearest thousand, unless otherwise indicated.

The results of operations for an interim period are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report for the year ended December 31, 2012.

On April 29, 2013, we acquired Ingenuity Systems, Inc., located in Redwood City, California (Ingenuity). Accordingly, as of April 29, 2013, all of the assets acquired and liabilities assumed were recorded at their respective fair values and our consolidated results of operations include Ingenuity’s operating results beginning April 29, 2013. On May 3, 2012, we acquired AmniSure International LLC, located in Boston, Massachusetts (AmniSure). Accordingly, as of May 3, 2012, all of the assets acquired and liabilities assumed were recorded at their respective fair values and our consolidated results of operations include AmniSure’s operating results beginning May 3, 2012.

The interim condensed consolidated financial statements of QIAGEN N.V. for the six-months ended June 30, 2013 were authorized for issue by the Supervisory Board on July 31, 2013. These interim condensed consolidated financial statements have not been audited or reviewed.

Significant Accounting Policies

The interim condensed consolidated financial statements were prepared based on the same accounting policies as those applied and described in the consolidated financial statements as at December 31, 2012 including the adoption of new standards and interpretations as of January 1, 2013.

Adoption of New and Amended Standards and Interpretations

- IAS 1, *'Financial statements presentation - presentation of items of other comprehensive income*' changes the grouping of items presented in other comprehensive income and affects its presentation. Items that could be reclassified to profit or loss at a future point would be presented separately from items that will never be reclassified. The amendment is effective for our 2013 Consolidated Financial Statements, and we have noted

within the Consolidated Statement of Comprehensive Income (Loss) which elements will, through recycling, impact net income in the future.

- IFRS 7, *'Financial instruments: Offsetting financial assets and financial liabilities*' these amendments would provide users with information that is useful in (a) evaluating the effect or potential effect of netting arrangements on an entity's financial position and (b) analyzing and comparing financial statements. We have adopted the amendments to IFRS 7 as of January 1, 2013 and the adoption did not have any impact on our consolidated financial statements.
- IFRS 10, '*Consolidated financial statements*' is mandatory for periods beginning on or after January 1, 2013. The standard provides additional guidance to assist in the determination of control where this is difficult to assess and defines the principle of control, and establishes control as the basis for consolidation. Under IFRS 10, subsidiaries are all entities (including special purpose entities) over which the Group has control. The Group controls an entity when the Group has power over an entity, is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect these returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases. We adopted IFRS 10 as of January 1, 2013 without significant impact.
- IFRS 11, '*Joint arrangements'*, effective for periods beginning on or after January 1, 2013, defines two types of joint arrangement: joint operations and joint ventures. Joint operations arise where a joint operator has rights to the assets and obligations relating to the arrangement and hence accounts for its interest in assets, liabilities, revenue and expenses. Joint ventures arise where the joint operator has rights to the net assets of the arrangement and hence equity accounts for its interest. Proportional consolidation of joint ventures is no longer allowed. We adopted IFRS 11 as of January 1, 2013 without significant impact.
- IFRS 12, '*Disclosures of interests in other entities*' includes the disclosure requirements for all forms of interests in other entities, including joint arrangements, associates, special purpose vehicles and other off-balance sheet vehicles. Disclosure requirements are not applicable for interim financial statements unless significant events and transactions in the interim period requires that they are provided. The new standard became effective for periods beginning on or after January 1, 2013.
- IFRS 13, '*Fair value measurement'*, aims to improve consistency and to reduce complexity by providing a precise definition of fair value and a single source of fair value measurement and disclosure requirements for use across IFRSs. The new standard became effective for periods beginning on or after January 1, 2013. We adopted IFRS 13 as of January 1, 2013 without impact.
- Amendments to IAS 19, '*Employee Benefits,'* which became mandatory for our 2013 Consolidated Financial Statements, aim to improve the understanding of how defined benefit plans affect an entity's financial position, financial performance and cash flows and are likely to impact the amount of actuarial gains and losses that will impact net income versus be allocated to other comprehensive income as remeasurements. Since we do not have any significant defined benefit plans, the amendments did not have a material impact to our financial statements.

Segment Reporting

We operate as one operating segment in accordance with IFRS 8 *Operating Segments*. Our chief operating decision maker (CODM) makes decisions based on the Company as a whole. In addition, we have a common basis of organization and types of products and services which derive revenues and consistent product margins. Accordingly, we operate and make decisions as one reporting unit. With revenues derived from our entire product and service offerings, it is not practicable to provide a detail of revenues for each group of similar products and services or for each customer group, as discrete financial information is not available. However, we do provide certain revenue information by customer class in our Management Report to allow better insight into our operations. This information is estimated using certain assumptions to allocate revenue among the customer classes.

Estimates

The preparation of the condensed consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates.

In preparing these condensed consolidated financial statements, the significant judgments made by management in applying accounting policies and the key sources of estimating uncertainty were the same as those that applied to the consolidated financial statements for the year ended December 31, 2012.

Impairments

During the six month period ended June 30, 2013, we recorded impairment charges in connection with restructuring activities as discussed in Note 4.

3. Acquisitions

Acquisitions have been accounted for as business combinations, and the acquired companies' results have been included in the accompanying condensed consolidated statements of income from their respective dates of acquisition. Our acquisitions have historically been made at prices above the fair value of the acquired net assets, resulting in goodwill, due to expectations of synergies of combining the businesses. These synergies include use of our existing infrastructure, such as sales force, shared service centers, distribution channels and customer relations, to expand sales of the acquired businesses' products; use of the infrastructure of the acquired businesses to cost-effectively expand sales of our products; and elimination of duplicative facilities, functions and staffing.

2013 Acquisition

On April 29, 2013, we acquired 100% of the outstanding common shares of Ingenuity Systems, Inc., the leading provider of software solutions that efficiently and accurately analyze and interpret the biological meaning of genomic data. The cash consideration totaled $107.0 million of which an amount of $0.2 million was unpaid as of June 30, 2013 and $10.0 million was retained in an escrow account to cover any claims for breach of any representations, warranties or indemnities. The acquisition of Ingenuity did not have a material impact to net sales, net income or earnings per share and therefore no proforma information has been provided herein.

The allocation of the purchase price is preliminary and is not yet finalized. The preliminary allocation of the purchase price is based upon preliminary estimates using information that was available to management at the time the financial statements were prepared and these estimates and assumptions are subject to change within the measurement period, up to one year from the acquisition date. Accordingly, the allocation may change. We continue to gather information about the fair value of certain assets and liabilities, including intangible assets acquired, deferred taxes and liabilities. Acquisition-related costs are expensed when incurred and are included in general and administrative, restructuring, integration and other expense in the accompanying condensed consolidated statements of income.

The preliminary purchase price allocation is as follows:

(in thousands)	Ingenuity Systems acquisition
Purchase Price:	
Cash consideration	$ 107,001
	$ 107,001
Preliminary Allocation:	
Cash and cash equivalents	$ 4,449
Accounts receivable	2,018
Prepaid and other current assets	1,712
Accounts payable	(2,662)
Accruals and other current liabilities	(14,438)
Fixed and other long-term assets	2,648
Non-current deferred tax asset	12,787
Developed technology, licenses and know-how	37,903
Tradenames	3,359
In-process research and development	2,069
Customer relationships	1,023
Goodwill	75,552
Deferred tax liability on fair value of identifiable intangible assets acquired	(19,015)
Liabilities assumed	(404)
	$ 107,001

The weighted-average amortization period for the intangible assets is 14.1 years. The goodwill acquired is not deductible for tax purposes.

Since the acquisition date, the results of Ingenuity are included in our consolidated results through June 30, 2013. Net sales totaled $2.9 million and and net loss attributable to the owners of QIAGEN N.V. was $1.4 million for the six-month period ended June 30, 2013. Acquisition-related costs for Ingenuity for the six-month period ended June 30, 2013 amounted to $0.5 million.

2011 Acquisition

During 2011, we acquired a majority shareholding in Ipsogen S.A., a publicly listed company founded in 1999 and based in Marseille, France, that is a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of applications in the field of hematology. During 2013, we have acquired additional Ipsogen S.A. shares for a total of $0.5 million and hold 89.93% of the Ipsogen S.A. shares as of June 30, 2013.

4. Restructuring

Late in 2011, we began a project to enhance productivity by streamlining the organization and freeing up resources for reallocation to strategic initiatives to help drive growth and innovation, strengthen our industry leadership position and improve longer-term profitability. This project aims to eliminate organizational layers and overlapping structures, actions that we expect will enhance our processes, speed and productivity. The last group of initiatives included actions to focus R&D activities on higher-growth areas in all customer classes, concentrate operations at fewer sites, and realign sales and regional marketing teams in the U.S. and Europe to better address customer needs in a more streamlined manner across the continuum from basic research to translational medicine and clinical diagnostics. A restructuring charge was taken in the second quarter of 2013 as part of this transformational project. The specific restructuring measures and associated estimated costs were based on

management's best business judgment under the existing circumstances at the time the estimates were made. If future events require changes to these estimates, such adjustments will be reflected prospectively in the applicable line item in the condensed consolidated statements of income.

Final initiatives were implemented in the second quarter of 2013 building on the earlier initiatives that have included focusing research and development activities on higher-growth areas in all customer classes, concentrating operations at fewer sites and capturing the benefits of shared service functions and outsourcing of non-core activities. We have realigned our sales and regional marketing teams in the U.S. and Europe to better address customer needs in a more streamlined manner across the continuum from basic research to translational medicine and clinical diagnostics. In addition, as an outcome of recent acquisitions, various Molecular Diagnostics research and development and marketing functions are being consolidated at our U.S. Maryland site. A restructuring charge was taken in the second quarter of 2013 as part of this transformational project. The specific restructuring measures and associated estimated costs were based on management's best business judgment under the existing circumstances at the time the estimates were made. If future events require changes to these estimates, such adjustments will be reflected prospectively in the applicable line item in the condensed consolidated statements of income.

In the first half of 2013, we recorded pretax charges of $65.1 million in general, administrative, restructuring and other. The pretax charges consist of $15.3 million for personnel related costs, $26.2 million of impairments, $2.1 million for contract termination costs, and $21.5 million of other costs including consulting costs. Additionally we recorded $36.9 million in cost of sales which includes $25.2 million of fixed and intangible asset impairments, $6.7 million for contract termination costs, $3.0 million for the write off of inventory, and $2.0 million for personnel costs. In the first half of 2012, we recorded pretax charges of $16.9 million in general, administrative, restructuring and other. Since 2011, we have incurred cumulative restructuring costs totaling $274.0 million which include $42.9 million for personnel related costs, $166.1 million of impairments, and $65.0 million of contract, consulting and other related costs. We expect further restructuring charges in the remainder of 2013 to complete this project.

The following table summarizes the components of the restructuring costs. At June 30, 2013 and December 31, 2012, restructuring accruals of $27.2 million and $4.9 million, respectively, were included in accrued and other liabilities in the accompanying condensed consolidated statements of financial position.

(in thousands)	Personnel Related	Facility Related	Contract and Other Costs	Total
Balance at December 31, 2012	$ 2,321	$ 2,466	$ 137	$ 4,924
Additional costs in 2013	17,285	—	8,680	25,965
Payments	(2,330)	(450)	(205)	(2,985)
Release of excess accrual	(525)	—	(25)	(550)
Foreign currency translation adjustment	57	(163)	(7)	(113)
Balance at June 30, 2013	**$ 16,808**	**$ 1,853**	**$ 8,580**	**$ 27,241**

The costs in the above table do not include consulting costs associated with third-party service providers that are assisting with executing the restructuring. We accrue for consulting costs as the services are provided.

5. Investments in Associates and Available for Sale Financial Instruments

We have made strategic investments in certain companies that are accounted for using the equity method of accounting. The method of accounting for an investment depends on the level of influence. We monitor changes in circumstances that may require a reassessment of the level of influence. We periodically review the carrying value of these investments for impairment, considering factors such as the most recent stock transactions and book values from the recent financial statements.

As of June 30, 2013 and December 31, 2012, we had a total of cost-method investments in non-publicly traded companies with carrying amounts of $15.1 million and $15.5 million, respectively, which are included in

non-current available for sale assets. These cost-method investments do not have a quoted market price in an active market and are measured at cost in accordance with IAS 39 because their fair value cannot be reliably measured. Changes in fair value of these cost-method investments are identified when there are events or changes in circumstances that may have a significant adverse effect on the fair value of the investments. For the six-month period ended June 30, 2013, we recorded an impairment of a cost method investment of $3.4 million in other expense, net.

6. Intangible Assets

The changes in intangibles assets in 2013 are summarized as follows:

(in thousands)	Intangibles	Goodwill
Balance at December 31, 2012	$ 946,602	$ 1,783,913
Additions	15,476	—
Acquisition	44,354	75,552
Amortization	(68,868)	—
Impairment losses	(34,095)	—
Foreign currency translation adjustments	(21,498)	(42,969)
Balance at June 30, 2013	**$ 881,971**	**$ 1,816,496**

In connection with the restructuring discussed more fully in Note 4, impairment charges of $34.1 million related to discontinued projects was recorded as $17.0 million in cost of sales and $17.1 million in general and administrative, restructuring, integration and other costs in the six-month period ended June 30, 2013. Cash paid for purchases of intangible assets during the six-months ended June 30, 2013 totaled $15.7 million of which $8.3 million is included in other non-current assets in the accompanying statement of financial position. Additionally, during the six-months ended June 30, 2013, we capitalized $8.1 million of development expenses.

The changes in the carrying amount of goodwill for the six-months ended June 30, 2013 resulted primarily from the acquisition of Ingenuity and changes in foreign currency translation.

7. Derivatives and Hedging

In the ordinary course of business, we use derivative instruments, including swaps, forwards and/or options, to manage potential losses from foreign currency exposures and variable rate debt. The principal objective of such derivative instruments is to minimize the risks and/or costs associated with global financial and operating activities. We do not utilize derivative or other financial instruments for trading or other speculative purposes. We recognize all derivatives as either assets or liabilities on the statement of financial position on a gross basis, measure those instruments at fair value and recognize the change in fair value in earnings in the period of change, unless the derivative qualifies as an effective hedge that offsets certain exposures. We do not offset the fair value of derivative instruments with cash collateral held or received from the same counterparty under a master netting arrangement.

During 2012, we held derivatives that qualified for hedge accounting, were classified as cash-flow hedges and matured late in 2012. For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. We did not record any hedge ineffectiveness related to any cash-flow hedges in earnings and did not discontinue any cash-flow hedges in 2012. The cash flows derived from derivatives, including those that are not designated as hedges, are classified in the operating section of the consolidated statements of cash flows. As of June 30, 2013 we did not have any derivatives that were accounted for as hedging instruments.

Foreign Currency Derivatives

As a globally active enterprise, we are subject to risks associated with fluctuations in foreign currencies in our ordinary operations. This includes foreign currency-denominated receivables, payables, debt, and other statement of financial positions including intercompany items. We manage balance sheet exposure on a group-wide basis using foreign exchange forward contracts, foreign exchange options and cross-currency swaps.

In 2012, we were party to cross-currency swaps with a notional amount of $120.0 million and which qualified as cash-flow hedges until maturity in November 2012.

Undesignated Derivative Instruments

We are party to various foreign exchange forward, option and swap arrangements which had, at June 30, 2013, an aggregate notional value of approximately $519.9 million and fair value of $7.4 million included in prepaid and other current assets and $2.7 million included in other current liabilities, respectively, and which expire at various dates through September 2013.

We were party to various foreign exchange forward and swap arrangements which had, at December 31, 2012, an aggregate notional value of approximately $574.5 million and fair values of $0.8 million and $12.9 million which are included in other assets and other liabilities, respectively, and which expired at various dates through April 2013.

The transactions were entered into to offset the effects from short-term balance sheet exposure to foreign currency exchange risk. Changes in the fair value of these arrangements were recognized in other income, net.

Fair Values of Derivative Instruments

The following table summarizes the fair value amounts of derivative instruments reported in the condensed consolidated statements of financial position as of June 30, 2013 and December 31, 2012:

	Derivatives in Asset Positions Fair value		**Derivatives in Liability Positions Fair value**	
(in thousands)	**6/30/2013**	**12/31/2012**	**6/30/2013**	**12/31/2012**
Undesignated derivative instruments				
Foreign exchange contracts	**$ 7,397**	$ 833	**$ (2,673)**	$ (12,911)
Total derivative instruments	**$ 7,397**	$ 833	**$ (2,673)**	$ (12,911)

Gains and Losses on Derivative Instruments

The following tables summarize the locations and gains and losses on derivative instruments for six months ended June 30, 2013 and 2012:

Six months ended June 30, 2013 (in thousands)	Gain/(loss) recognized in equity	Location of (gain) loss in income statement	(Gain) loss reclassified from equity into income	Gain (loss) recognized in income
Cash-flow hedges				
Foreign exchange contracts	$ —	Other (expense) income, net	$ —	n/a
Total	$ —		$ —	$ —
Undesignated derivative instruments				
Foreign exchange contracts	n/a	Other (expense) income, net	n/a	$ 6,333

Six months ended June 30, 2012 (in thousands)	Gain/(loss) recognized in equity	Location of (gain) loss in income statement	(Gain) loss reclassified from equity into income	Gain (loss) recognized in income
Cash-flow hedges				
Foreign exchange contracts	3,541	Other (expense) income, net	(2,978)	n/a
Total	$ 3,541		$ (2,978)	n/a
Undesignated derivative instruments				
Foreign exchange contracts	n/a	Other (expense) income, net	n/a	$ (1,028)

The amounts noted in the tables above do not include any adjustments for the impact of deferred income taxes. Gains and losses recognized on foreign exchange contracts are included in financial income (expense).

8. Fair value measurements

Financial Instruments are measured at fair value according the following hierarchy which prioritizes the inputs used in measuring fair value as follows:

- Level 1: Quoted prices in active markets for the same instrument;
- Level 2: Quoted prices in active markets for similar instruments or other valuation techniques for which all significant inputs are based on observable market data, either directly or indirectly;
- Level 3: Valuation techniques for which any significant input is not based on observable data

Our assets and liabilities measured at fair value on a recurring basis consist of current available-for-sale financial instruments, which are classified in Level 1 and Level 2 of the fair value hierarchy, derivative financial instruments used to hedge currency and interest rate risk, which are classified in Level 2 of the fair value hierarchy, and contingent consideration accruals which are classified in Level 3 of the fair value hierarchy and are shown in the tables below. In determining fair value for Level 2 instruments, we apply a market approach, using quoted active market prices relevant to the particular instrument under valuation, giving consideration to the credit risk of both the respective counterparty to the contract and the Company. To determine our credit risk we estimated our credit rating by benchmarking the price of outstanding debt to publicly-available comparable data from rated companies. Using the estimated rating, our credit risk was quantified by reference to publicly-traded debt with a corresponding rating. We value contingent consideration liabilities using level 3 unobservable inputs, applying the income approach, such as the discounted cash flow technique, or the probability-weighted scenario method. Contingent consideration arrangements obligate us to pay the sellers of an acquired entity if specified future events occur or conditions are met such as the achievement of technological or revenue milestones. We use

various key assumptions, such as the probability of achievement of the milestones and the discount rate, to represent the non-performing risk factors and time value when applying the income approach. We regularly review the fair value of the contingent consideration, and measurement period adjustments are reflected in goodwill and all other changes in the accrual are recognized in the condensed consolidated statement of income in the line items commensurate with the underlying nature of milestone arrangements.

The following table presents our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2013:

(in thousands)	Level 1	Level 2	Level 3	June 30, 2013
Current available-for-sale financial instruments	$ 7,979	$ 65,400	$ —	**$ 73,379**
Foreign exchange contracts	—	7,397	—	**7,397**
Assets	**$ 7,979**	**$ 72,797**	**$ —**	**$ 80,776**
Foreign exchange contracts	$ —	$ 2,673	$ —	**$ 2,673**
Contingent consideration	—	—	14,232	**14,232**
Liabilities	**$ —**	**$ 2,673**	**$ 14,232**	**$ 16,905**

As of December 31, 2012, we held the following financial instruments measured at fair value:

(in thousands)	Level 1	Level 2	Level 3	December 31, 2012
Current available-for-sale financial instruments	$ 7,989	$ 82,462	$ —	**$ 90,451**
Foreign exchange contracts	—	833	—	**833**
Assets	**$ 7,989**	**$ 83,295**	**$ —**	**$ 91,284**
Foreign exchange contracts	$ —	$ 12,911	$ —	**$ 12,911**
Contingent consideration	—	—	18,983	**18,983**
Liabilities	**$ —**	**$ 12,911**	**$ 18,983**	**$ 31,894**

For financial liabilities with Level 3 inputs, the following table summarizes the activity for the six-months ended June 30, 2013.

(in thousands)	Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Contingent Consideration
Beginning Balance at January 1st, 2013	**$ 18,983**
Additions from changes in estimates	**1,385**
Payments	**(181)**
Gain included in earnings	**(5,936)**
Foreign currency translation adjustments	**(19)**
Ending balance at June 30, 2013	**$ 14,232**

During 2013, a gain for the reduction in the fair value of contingent consideration totaling $5.9 million is included in the condensed consolidated statement of income of which $5.4 million was recognized in cost of sales and $0.5 million was recognized in general and administrative, restructuring, integration and other.

The carrying values of financial instruments, including cash and equivalents, accounts receivable, accounts payable and other accrued liabilities, approximate their fair values due to their short-term maturities. The estimated fair value of long-term debt as disclosed in Note 9 was based on current interest rates for similar types of borrowings. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. There were no fair value adjustments in the six-month periods ended June 30, 2013 and 2012 for nonfinancial assets or liabilities required to be measured

at fair value on a nonrecurring basis other than the impairment of intangible assets and manufacturing equipment that were written-down in connection with restructuring activities as discussed in Note 4 and the impairment of a cost method investment as discussed in Note 5.

9. Financial Debts

Our credit facilities available at June 30, 2013 total €438.0 million (approximately $572.9 million). This includes a €400.0 million syndicated multi-currency revolving credit facility expiring December 2016 of which no amounts were utilized at June 30, 2013 or at December 31, 2012, and four other lines of credit amounting to €38.0 million with no expiration date, none of which were utilized as of June 30, 2013 or at December 31, 2012. The €400.0 million facility can be utilized in euro, U.K pound or U.S. dollar and bears interest of 0.8% to 2.35% above three months EURIBOR, or LIBOR in relation to any loan not in euro, and is offered with interest periods of one, two, three, six or twelve months. The commitment fee is calculated based on 35% of the applicable margin. The revolving facility agreement contains certain financial and non-financial covenants, including but not limited to, restrictions on the encumbrance of assets and the maintenance of certain financial ratios. We were in compliance with these covenants at June 30, 2013. The credit facilities are for general corporate purposes.

In October 2012, we completed a private placement through the issuance of new senior unsecured notes at a total amount of $400 million with a weighted average interest rate of 3.66% (settled on October 16, 2012). The notes were issued in three series: (1) $73 million 7-year term due in 2019 (3.19%); (2) $300 million 10-year term due in 2022 (3.75%); and (3) $27 million 12-year term due in 2024 (3.90%). We paid $2.1 million in debt issue costs which are being amortized through interest expense over the lifetime of the notes. The note purchase agreement contains certain financial and non-financial covenants, including but not limited to, restrictions on priority indebtedness and the maintenance of certain financial ratios. We were in compliance with these covenants at June 30, 2013. Based on an estimation using the changes in the U.S. Treasury rates, the fair value of these senior notes at June 30, 2013 was approximately $381.8 million.

At June 30, 2013, total long-term debt was approximately $846.4 million, of which $0.7 million is current. We believe that funds from operations, existing cash and cash equivalents, and availability of financing facilities as needed, will be sufficient to fund our debt repayments coming due in the next twelve months.

Total long-term debt consists of the following:

(in thousands)	June 30, 2013	December 31, 2012
3.25% Convertible Note due 2024	145,000	145,000
1.5% Convertible Note due 2026	300,000	295,641
3.19% Series A Senior Notes due 2019	73,000	73,000
3.75% Series B Senior Notes due 2022	300,000	300,000
3.90% Series C Senior Notes due 2024	27,000	27,000
Other notes payable bearing interest up to 6.28% and due through 2015	1,356	1,992
Total current and non-current financial debts	**846,356**	**842,633**
Less: current portion of financial debts	727	948
Total non-current financial debts	**$ 845,629**	**$ 841,685**

With reference to the detailed disclosure in the Annual Report 2012 and based on an estimation using available over-the-counter market information on the convertible bonds, the fair value of the convertible bond issued by QIAGEN Finance (Luxembourg) S.A., at June 30, 2013 and December 31, 2012 was approximately $225.7 million and $209.7 million, respectively. The effective interest rate of the Notes amounts to 1.5%. The Company has reserved 11.5 million shares of common stock for issuance in the event of conversion.

The fair value of the the convertible bond issued by QIAGEN Euro Finance (Luxembourg) S.A., at June 30, 2013 and December 31, 2012 was approximately $365.3 million and $358.4 million, respectively. The effective interest rate of

the Notes amounts to 3.25%. The Company has reserved 15.0 million of common stock for issuance in the event of conversion.

10. Income Taxes

The provision for income taxes is based upon the estimated annual effective tax rates for the year applied to the current period income before tax plus the tax effect of any significant unusual items, discrete events or changes in tax law. Our operating subsidiaries are exposed to effective tax rates ranging from zero to approximately 42%. Fluctuations in the distribution of pre-tax income among our operating subsidiaries can lead to fluctuations of the effective tax rate in the condensed consolidated financial statements. In the six-month periods ended June 30, 2013 and 2012, the effective tax rates were (30.0)% and 6.7%. Our negative rates in 2013 are primarily the result of restructuring charges and impairments which are attributable to higher taxed jurisdictions

We conduct business globally and, as a result, file numerous consolidated and separate income tax returns in The Netherlands, Germany, Switzerland and the U.S. federal jurisdiction, as well as in various other state and foreign jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. Our subsidiaries are generally no longer subject to income tax examinations by tax authorities for years before 2008.

As of June 30, 2013, residual Netherlands income taxes have not been provided on the undistributed earnings of the majority of our foreign subsidiaries as these earnings are considered to be either permanently reinvested or can be repatriated tax free.

11. Inventories

The components of inventories consist of the following as of June 30, 2013 and December 31, 2012:

(in thousands)	June 30, 2013	December 31, 2012
Raw materials	**$ 25,056**	$ 29,755
Work in process	**29,148**	34,231
Finished goods	**78,442**	71,307
Total inventories	**$ 132,646**	$ 135,293

12. Share Repurchase Program

In 2012, the Supervisory Board approved a program authorizing management to purchase up to a total of $100 million of our common shares (excluding transaction costs). In 2013, we repurchased an additional 3.1 million QIAGEN shares for $63.3 million. We completed the share repurchase program in April 2013 having repurchased between October 2012 and April 2013 a total of 5.1 million QIAGEN shares for a total of $99.0 million. The cost of repurchased shares is included in treasury stock and reported as a reduction in total equity when a repurchase occurs. Repurchased shares will be held in treasury in order to satisfy various obligations, which include exchangeable debt instruments and employee share-based remuneration plans.

In July 2013, we announced our intention to exercise the authorization granted by the Annual General Meeting of Shareholders on June 26, 2013, to purchase up to $100 million of our common shares (excluding transaction costs). Based on the closing price on July 29, 2013, this represents approximately 5.0 million common shares. Details of the repurchase program will be announced before its actual commencement in line with Article 4, Section (2) of EC regulation 2273/2003 (so called Safe Harbor). Repurchased shares will be held in treasury in order to satisfy obligations for exchangeable debt instruments and employee share-based remuneration plans.

13. Earnings per Common Share

We present basic and diluted earnings per share. Basic earnings per share is calculated by dividing the net (loss) income attributable to the owners of QIAGEN N.V. by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that would occur if all "in the money" securities to issue common shares were exercised. In the six months ended June 30, 2013 and 2012 the effect of the convertible notes (discussed in Note 9) was excluded from calculating diluted earnings per share as it was antidilutive. Due to the net loss for the six-month period ended June 30, 2013, stock options and restricted stock units representing approximately 4.1 million weighted-average shares of common stock were excluded from the computation of diluted net loss because the impact would have been antidilutive.

The following schedule summarizes the information used to compute earnings per common share:

	Six months ended June 30,	
(in thousands, except per share data)	**2013**	**2012**
Net (loss) income attributable to the owners of QIAGEN N.V.	**$ (56,971)**	$ 58,860
Weighted average number of common shares used to compute basic net income per common share	**233,699**	235,302
Dilutive effect of stock options and awards	**—**	1,963
Weighted average number of common shares used to compute diluted net income per common share	**233,699**	237,265
Outstanding options and awards having no dilutive effect, not included in above calculation	**1,944**	3,907
Outstanding convertible notes having no dilutive effect, not included in above calculation	**26,467**	26,467
Basic (loss) earnings per common share attributable to the owners of QIAGEN N.V.	**$ (0.24)**	$ 0.25
Diluted (loss) earnings per common share attributable to the owners of QIAGEN N.V.	**$ (0.24)**	$ 0.25

14. Commitments and Contingencies

Contingent Consideration Commitments

Pursuant to the purchase agreements for certain acquisitions, we could be required to make additional contingent cash payments totaling up to $129.0 million based on the achievement of certain revenue and operating results milestones as follows: $14.2 million in the remainder of 2013, $23.4 million in 2014, $16.2 million in 2015, $17.5 million in 2016, $7.0 million in 2017, and $50.7 million payable in any 12-month period from now until 2017 based on the accomplishment of certain revenue targets, the launch of certain products or the grant of certain patent rights. Of the $129.0 million total contingent obligation, we have assessed the fair value at June 30, 2013 to be $14.2 million, where $9.5 million and $4.7 million are included in other current liabilities and other non-current liabilities, respectively, as of June 30, 2013.

Preacquisition Contingencies

In connection with certain acquisitions, amounts were paid into escrow accounts to cover certain preacquisition contingencies assumed in the acquisition. The escrow amounts that can be claimed by QIAGEN are recorded as an asset in prepaid and other current assets and amount to $2.5 million as of June 30, 2013 ($7.5 million as of December 31, 2012). In addition, we have recorded $0.1 million for preacquisition contingencies as a liability under other current liabilities as of June 30, 2013 ($5.5 million as of December 31, 2012).

Contingencies

In the ordinary course of business, we provide a warranty to customers that our products are free of defects and will conform to published specifications. Generally, the applicable product warranty period is one year from the date of delivery of the product to the customer or of site acceptance, if required. Additionally, we typically provide limited warranties with respect to our services. From time to time, we also make other warranties to customers, including warranties that our products are manufactured in accordance with applicable laws and not in violation of third-party rights. We provide for estimated warranty costs at the time of the product sale. We believe our warranty reserves of $4.3 million and $4.4 million as of June 30, 2013 and December 31, 2012, respectively, appropriately reflect the estimated cost of such warranty obligations.

Litigation

From time to time, QIAGEN may be party to legal proceedings incidental to its business. As of June 30, 2013, certain claims, suits or legal proceedings arising out of the normal course of business have been filed or were pending against QIAGEN or its subsidiaries. These matters have arisen in the ordinary course and conduct of business, as well as through acquisition. Although it is not possible to predict the outcome of such litigation, we assess the degree of probability and evaluate the reasonably possible losses that we could incur as a result of these matters. We accrue for any estimated loss when it is probable that a liability has been incurred and the amount of probable loss can be estimated. Based on the facts known to QIAGEN and after consultation with legal counsel, management believes that such legal proceedings will not have a material adverse effect on QIAGEN's financial position or results of operations.

15. Share-Based Payments

Stock Options

During the six-month periods ended June 30, 2013 and 2012, we granted options to purchase 0.5 million common shares.

The unrecognized share-based compensation expense related to employee stock option awards, less estimated forfeitures, was approximately $3.8 million, as of June 30, 2013 which will be recognized over a period of 1.41 years.

Stock Awards

Stock-based awards consist of restricted stock units, which have time-based vesting, and performance stock units which have a performance hurdle in addition to the time vesting. During the six months ended June 30, 2013 and 2012, we granted 2.3 million and 2.4 million stock awards, respectively.

At June 30, 2013, there was $76.3 million remaining in unrecognized compensation expense, less estimated forfeitures, related to these awards which will be recognized over a period of 3.08 years.

Share-Based Compensation Expense

Total share-based compensation expense for the six-month periods ended June 30, 2013 and 2012 is comprised of the following:

(in thousands)	Six months ended June 30, 2013	2012
Cost of sales	**$ 2,228**	$ 1,511
Research and development	**3,434**	2,460
Sales and marketing	**5,947**	3,711
General and administrative, restructuring, integration and other	**9,815**	7,001
Share-based compensation expense before taxes	**21,424**	14,683
Less: income tax benefit	**5,252**	7,629
Net share-based compensation expense	**$ 16,172**	$ 7,054

During the six-months periods ended June 30, 2013, we recognized expense of $1.4 million in connection with retirement provisions for Supervisory Board members. No compensation cost was capitalized in inventory at June 30, 2013 or December 31, 2012 as the amounts were not material.

16. Related Party Transactions

From time to time, we engage in transactions with companies in which we hold interests all of which are individually and in the aggregate immaterial. Compared to December 31, 2012, no significant changes have occurred to the related party transactions as of June 30, 2013.

QIAGEN N.V.

Responsibility statement of the Management Board to the condensed consolidated financial statements for the six months ended June 30, 2013

(unaudited)

The Managing Board of QIAGEN declares that, to the best of their knowledge,

- the condensed consolidated financial statements for the six months ended June 30, 2013 (half-year financial statements) give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the entities included in the consolidation;
- the management report gives a true and fair view of the important events of the past six-month period and their impact on the half-year financial statements, as well as the principal risks and uncertainties for the six-month period to come, and the most important related party transactions as required by provision 5.25d section 2 sub (c) of the Dutch act on financial supervision (*Wet op het financieel toezicht*).

Venlo, August 2, 2013

QIAGEN N.V.

/s/ Peer M. Schatz	/s/ Roland Sackers
CEO	CFO

This section contains a number of forward-looking statements. These statements are based on current management expectations, and actual results may differ materially. Among the factors that could cause actual results to differ from management's expectations are those described in "Risk Factors" and "Forward-looking and Cautionary Statements" below.

Forward-looking and Cautionary Statements

This report contains forward-looking statements that are subject to risks and uncertainties. These statements can be identified by the use of forward-looking terminology, such as "believe," "hope," "plan," "intend," "seek," "may," "will," "could," "should," "would," "expect," "anticipate," "estimate," "continue" or other similar words. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. We caution investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: risks associated with our expansion of operations, including the acquisition of new businesses; variability in our operating results from quarter to quarter; management of growth, international operations, and dependence on key personnel; intense competition; technological change; our ability to develop and protect proprietary products and technologies and to enter into and maintain collaborative commercial relationships; our future capital requirements; general economic conditions and capital market fluctuations; and uncertainties as to the extent of future government regulation of our business. As a result, our future success involves a high degree of risk. For further information, refer to the more specific risks and uncertainties discussed on pages 23 to 41 of the 2012 Annual Report.

Results of Operations

Overview

We are the world's leading provider of innovative Sample & Assay Technologies, based on independent market studies of United States and European market shares for our products and technologies. Our automated systems and consumable products empower customers to transform raw biological samples into valuable molecular information. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample, such as blood or tissue. Assay technologies are then used to amplify, enrich and provide results for analysis of biomolecules, such as the DNA of a virus or a mutation of a gene.

We sell our products, sample and assay kits known as consumables and automated instrumentation systems using those technologies, to four major customer classes:

- **Molecular Diagnostics**-healthcare providers supporting many aspects of patient care including prevention, profiling of diseases, personalized healthcare and point of need testing
- **Applied Testing**- government or industry customers using molecular technologies in fields such as forensics, veterinary diagnostics and food safety testing
- **Pharma**-drug discovery and development efforts of pharmaceutical and biotechnology companies
- **Academia**-researchers exploring the secrets of life such as the mechanisms and pathways of diseases, and in some cases translating that research into drug targets or commercial applications

We market products in more than 100 countries throughout the world. We have established subsidiaries in markets we believe have the greatest sales potential, including countries throughout Europe, Asia, the Americas and Australia. We also work with specialized independent distributors and importers. As of June 30, 2013, we employed approximately 4,050 people in more than 35 locations worldwide.

Among recent developments in 2013:

- **Personalized Healthcare:** We continue to advance our global leadership in companion diagnostics. In July the

U.S. Food and Drug Administration (FDA) approved the therascreen EGFR RGQ PCR Kit as a companion diagnostic to guide the use of the new targeted therapy Gilotrif® (afatinib) from Boehringer Ingelheim that also received FDA approval for use in metastatic non-small cell lung cancer (NSCLC) patients. This follows the 2012 launch of the therascreen KRAS RGQ PCR Kit paired for use with Erbitux® (cetuximab) from Eli Lilly and Bristol-Myers Squibb for metastatic colorectal cancer patients. Also in May, the new QIAGEN (Suzhou) Translational Medicine Center opened on China's BioBAY campus, aiming to accelerate the development of new biomarkers for companion diagnostics. We have also expanded our portfolio of co-development projects in 2013 with confidential agreements that include partnership extensions as well as projects with new pharmaceutical companies.

- **Next-generation sequencing (NGS):** We are moving ahead as planned on a strategic initiative to create an innovative sample-to-result workflow incorporating the GeneReader™ benchtop NGS sequencer designed to drive routine use of next-generation sequencing in clinical research and diagnostics. We have placed the system with select customers for early testing and are preparing for the phase rollout of this complete workflow beginning later this year. We continue to expand our NGS portfolio of GeneRead™ DNAseq gene panels, integrating these products with the recently acquired Ingenuity portfolio of biological data interpretation solutions. The current portfolio of nine gene panels for use in cancer is aligned with interpretation based on Ingenuity Variant Analysis™ and is being expanded to 20 gene panels for use in cancer and other disease areas. We also recently launched a full range of universal sample and library preparation products for NGS.
- **Leadership in biological data interpretation:** Initiatives are under way to integrate Ingenuity Systems, Inc., the leading provider of solutions to quickly and accurately analyze and interpret biological data, into QIAGEN's global commercial network following the acquisition in April 2013. New technologies such as next-generation sequencing (NGS) are generating growing volumes of complex data, and Ingenuity's solutions address the need to quickly turn raw data into actionable information that is scientifically and clinically relevant. Ingenuity announced in June that more than 2,500 users representing over 1,000 leading institutions so far have adopted Ingenuity Variant Analysis™, a market-leading solution for the interpretation of NGS data based on the Ingenuity Knowledge Base, which provides researchers access to a vast, expertly curated system of biomedical information. Interpretation of raw biological data is considered one of the most significant challenges in NGS applications, and for which QIAGEN's Ingenuity portfolio provides powerful solutions to address this bottleneck.
- **Access to exosomes for NGS and real-time PCR workflows**: We have entered a partnership with Exosome Diagnostics Inc. to develop and commercialize high-performance sample preparation kits to enable analysis of key gene mutations and gene expression levels based on biofluids such as blood, urine and cerebrospinal fluid. The combination of Exosome's technology with components of QIAGEN's consumables and automation platforms will offer researchers, drug developers and physicians the potential to take repeated, accurate genetic "snapshots" of diseases from a patient's biofluids without need for tissue biopsies. Standardized, easy-to-use exosome workflows will offer superior testing solutions spanning basic research and personalized healthcare based on real-time PCR, pyrosequencing and NGS workflows. The first product launches from this collaboration are planned for 2014.
- **QIAsymphony:** We are well on track to surpass 1,000 cumulative placements during 2013 for the QIAsymphony automation platform, the industry's first modular sample-to-result system that runs commercial assays as well as laboratory-developed tests. U.S. launch of the therascreen EGFR test adds to the growing menu of FDA-approved diagnostics running on the Rotor-Gene Q MDx, a real-time PCR platform within the QIAsymphony family. Building on the more than 750 placements at the end of 2012, demand remains strong for QIAsymphony among customers in both Molecular Diagnostics and the Life Sciences.
- **HPV testing market trends:** We maintain a solid leadership position in the U.S. market segment for cervical cancer screening with its digene HC2 Test, which ranks as the “gold standard” FDA-approved molecular test for HPV screening based on clinical data, annual sales and testing volumes. In June, we announced that a U.S. reference laboratory customer for this test had made public a new non-exclusive agreement to consolidate the purchase of products for a range of women's health diagnostics, including HPV tests, with a competing supplier, but that this customer will continue to offer the digene HC2 Test to its customers. We expect that sales related to this customer development represent less than 2% of anticipated total net sales for 2014, and also expect that sales of these HPV screening products will represent less than 10% of total net sales for the year. We continue to engage with other U.S. customers to reach new multi-year agreements for the digene HC2 Test in light of the price-driven pressure following the entry of new competitors.
- **Growing efficiently and effectively:** We announced the completion of a major project to improve efficiency and effectiveness throughout the Company, streamlining the organization and freeing up resources for reallocation to strategic initiatives. The last group of initiatives included actions to focus R&D activities on higher-growth areas in all customer classes, concentrate operations at fewer sites, and realign sales and regional marketing teams in the U.S. and Europe to better address customer needs in a more streamlined manner across the continuum from

basic research to translational medicine and clinical diagnostics. A restructuring charge was taken in the second quarter of 2013 as part of completing this transformational project. We expect further restructuring charges in the remainder of 2013 to complete this project.

Recent Acquisitions

We have made a number of strategic acquisitions, expanding our technology and product offerings as well as extending our geographic presence. These transactions include:

- On April 29, 2013, we acquired Ingenuity Systems, Inc., the leading provider of software solutions that efficiently and accurately analyze and interpret the biological meaning of genomic data. Ingenuity, a privately-held U.S. company based in California's Silicon Valley, created a market leading, expertly curated knowledge system of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems. New technologies such as next-generation sequencing (NGS) are now generating more data in a single year than was created in all prior history, making the analysis and interpretation of this extensive and very complex biological data a critical success factor.

- In June 2012, we unveiled an initiative to enter the NGS market, including our early 2012 acquisition of Intelligent Bio-Systems, Inc., which added important expertise and innovative technologies in this emerging field. Our NGS initiative aims to expand next-generation sequencing technologies from the current focus on life science research into routine use in clinical research and molecular diagnostics. The expected sample-to-result workflows will incorporate a next-generation benchtop sequencer, our QIAcube and QIAsymphony automation platforms, leading sample preparation solutions, specialized gene panels and GeneGlobe (www.geneglobe.com) portfolio of more than 60,000 well-defined and characterized molecular assays. New bioinformatics, including NGS solutions from a new collaboration with SAP AG, will handle clinical data produced in next-generation sequencing. Our new NGS platform is expected to be phased into the market in 2013.

- In May 2012, we acquired AmniSure International LLC, including the AmniSure® assay for determining whether a pregnant woman is suffering rupture of fetal membranes (ROM), a widespread cause of premature delivery and neonatal complications. This product, which is approved in the U.S. and many other markets, is expected to be catalytic for our Point of Need portfolio.

Our financial results include the contributions of our recent acquisitions from the date of acquisition, as well as costs related to the acquisitions and integrations of the acquired companies, such as the relocation and closure of certain facilities.

We determined that we operate as one business segment in accordance with IFRS 8, *Operating Segments.* Our chief operating decision maker (CODM) makes decisions on business operations and resource allocation based on evaluations of the QIAGEN Group as a whole. With revenues derived from our entire product and service offerings, it is not practicable to provide a detail of revenues for each group of similar products and services or for each customer group, as full discrete financial information is not available. However, we do provide certain revenue information by customer class to allow better insight into our operations. This information is estimated using certain assumptions to allocate revenue among the customer classes.

Six-Month Period Ended June 30, 2013, compared to Six-Month Period Ended June 30, 2012

Net Sales

For the six-month period ended June 30, 2013, net sales was $618.8 million compared to $603.6 million for the same period in 2012. Net sales advanced 3% in the six-month period ended June 30, 2013 compared to the same period of 2012, on growth in all regions, particularly in the Europe/Middle East/ Africa region, while Molecular Diagnostics more than compensated for largely unchanged sales in the other customer classes. The ongoing product portfolio provided 1% of growth, while Ingenuity and AmniSure provided approximately two percentage points of additional growth. Currency movements had no significant impact on reported sales growth in the six-month period ended June 30, 2013.

Geographic regions: In 2013, all regions advanced at single-digit rates. The Asia-Pacific / Japan region (+1%, 19% of sales) grew on double-digit gains in China, India and Singapore. The Europe / Middle East / Africa region (+3%, 32% of sales) rose on improving results in Turkey, the Nordic region and the United Kingdom. The Americas (+2%, 48% of sales) was led by Brazil and Mexico, while the U.S. was stable as lower sales of products used for HPV (human

papillomavirus) screening were offset by growth in the rest of the product portfolio. Sales in our top seven emerging markets (China, Brazil, Turkey, Korea, India, Russia and Mexico) rose 15% and represented 12% of total sales.

Product categories: Consumables and related revenues (+4%, 88% of sales) rose across all customer classes, and were led by growth in Applied Testing and Molecular Diagnostics. Contributions from Ingenuity recorded in this product category also supported underlying sales growth in Academia and Pharma. Instruments (-6%, 12% of sales) were lower as a result of the ongoing transition among Molecular Diagnostics customers to reagent rental agreements for QIAsymphony automation system placements, where revenues are recognized over a multi-year period, and also due to lower capital spending trends in Pharma, Applied Testing and Academia. Pharma delivered the strongest growth, while Academia sales were unchanged compared to the year-ago period. Instrument sales were significantly lower in Applied Testing against very strong results in the second quarter of 2012.

Customer classes: In the first half of 2013, Molecular Diagnostics rose 7% compared to the same period in 2012 and represented 50% of sales, and sales were up 18% excluding the global HPV franchise. 2013 improvement in sales of consumables more than offset a high-single-digit drop in instrument sales, which fell mainly due to emphasis on QIAsymphony under multi-year reagent rental agreements. In Prevention, the QuantiFERON-TB test for detection of latent tuberculosis (TB) again delivered more than 20% growth on successful market penetration initiatives, particularly in the U.S. and the Asia-Pacific region. Sales of products for HPV testing (-10%, 15% of sales) declined with sales continuing to decline in the U.S. due to implementation of multi-year customer agreements in light of new competitor pricing actions but rising in the Asia-Pacific / Japan region. In Profiling, consumables sales rose at a robust double-digit pace, supported by QIAsymphony placements. Personalized Healthcare sales were slightly higher as companion diagnostic assays was partially offset by lower revenues from co-development projects compared to the same period in 2012. In Point of Need, the AmniSure assay continued to benefit from integration into QIAGEN's global commercial network following the May 2012 acquisition.

In the first half of 2013, Applied Testing sales were unchanged compared to the same period in 2012 and represented 8% of sales and faced a tough comparison against high sales growth in the year-ago period, which included contributions from the 2012 launch of the QIAsymphony automation platform's application package for this customer class. In 2013, consumables grew based on the ongoing business expansion in human identification / forensics, veterinary medicine and food safety, but this was offset by significantly lower instrument sales.

In the first half of 2013, Pharma sales were unchanged compared to the same period in 2012 and represented 19% of sales and reflect the ongoing adverse impact of restructuring activities and site consolidations among some customers which were offset by the underlying sales growth and first-time contributions from Ingenuity.

In the first half of 2013, Academia sales declined 4% compared to the same period in 2012 and represented 23% of sales. Underlying sales gains in consumables were supported by first-time contributions from Ingenuity, while instrument sales were largely unchanged compared 2012. We continue to see very cautious buying patterns among customers in the U.S. and in certain areas of Europe, primarily due to concerns about the implementation of the U.S. government sequestration that took effect in March 2013 as well as European constrained budgets.

Gross Profit

Gross profit for the six-month period ended June 30, 2013, was $368.4 million (60% of net sales) as compared to $392.0 million (65% of net sales) for the same period in 2012. Generally, our consumable sample and assay products have a higher gross margin than our instrumentation products and service arrangements. Fluctuations in the sales levels of these products and services can result in fluctuations in gross margin between periods. Additionally in 2013 in connection with our restructuring efforts we recorded $36.9 million in cost of sales which includes $25.2 million of impairments, $6.7 million for contract termination costs, $3 million for the write off of inventory, and $2.0 million for personnel costs. Further, amortization expense related to developed technology and patent and license rights, which have been acquired in business combinations, is included in cost of sales. For the six-month period ended June 30, 2013 the amortization expense on acquisition-related intangibles within cost of sales decreased to $37.7 million compared to $40.0 million in the same period of 2012. We expect that our acquisition-related intangible amortization will increase as a result of future acquisitions.

Research and Development Expense

Research and development expenses increased to $65.4 million (11% of net sales) in the first half of 2013, as compared to $60.7 million (10% of net sales) in the same period of 2012. The increase in research and development expense in 2013 reflects the May 2013 acquisition of Ingenuity. Our business combinations, along with the acquisition of new technologies, may continue increase our research and development costs. As we continue to discover, develop and acquire new products and technologies, we expect to incur additional expenses related to facilities, licenses and

employees engaged in research and development efforts. Additionally, research and development costs are expected to increase as a result of seeking regulatory approvals, including U.S. FDA Pre-Market Approval (PMA), U.S. FDA 510(k) clearance and EU CE approval of certain assays or instruments. We have a strong commitment to innovation and expect to continue to make investments in our research and development efforts.

Sales and Marketing Expense

Sales and marketing expenses increased by 7% to $201.2 million (33% of net sales) for the six-month period ended June 30, 2013, from $187.5 million (31% of net sales) for the same period in 2012. Sales and marketing expenses are primarily associated with personnel, commissions, advertising, trade shows, publications, freight and logistics expenses and other promotional expenses. Starting January 1, 2013, the United States began imposing a 2.3% excise tax on the sale, including leases, of any "taxable medical device," that is any FDA-regulated device intended for human use, under the U.S. healthcare reform laws enacted in 2010. The excise tax is included in sales and marketing expense. In addition, the sales and marketing expenses include the costs of maintaining separate sales organizations addressing customers in Molecular Diagnostics, Applied Testing, Pharma and Academia. As part of our current restructuring efforts, in the second quarter of 2013 we have realigned our sales and regional marketing teams in the U.S. and Europe to better address customer needs in a more streamlined manner across the continuum from basic research to translational medicine and clinical diagnostics. We anticipate that sales and marketing costs will continue to increase along with new product introductions and growth in sales of our products, but we expect sales and marketing costs will grow at a slower rate than our overall revenue growth over the long term.

General and Administrative, Integration and Other Expense

During the six months ended June 30, 2013, we recorded general and administrative, restructuring and related costs of $123.3 million, as compared to $66.7 million for the same period in 2012. The net increase includes $65.1 million in restructuring costs in 2013 related to internal restructuring of subsidiaries, including severance and retention costs, plus increased costs in connection with our 2012 acquisitions, partially offset by operational efficiencies. This includes fixed and intangible asset impairment charges of $26.2 million. The restructuring costs primarily relate to a project we began in late 2011 to enhance productivity by streamlining the organization and freeing up resources for reallocation to strategic initiatives to help drive growth and innovation, strengthen our industry leadership position and improve longer-term profitability. This project eliminated organizational layers and overlapping structures, actions that will enhance our processes, speed and productivity. In connection with the integration of the acquired companies, we aim to improve efficiency in general and administrative operations. As we further integrate the acquired companies and pursue other opportunities to gain efficiencies, we expect to continue to incur additional business integration and restructuring costs in 2013. Over time, we believe the integration and restructuring activities will reduce expenses as we improve efficiency in operations.

Financial Income (Expense)

For the six months ended June 30, 2013, financial income increased to $2.5 million from $2.4 million in the same period of 2012. The financial income primarily reflects the changes in our short-term investments and the changing interest rates thereon.

Financial expense increased to $19.9 million in the six-month periods ended June 30, 2013, as compared to $15.5 million for the same period of 2012.

Liquidity and Capital Resources

To date, we have funded our business primarily through internally generated funds, debt and private and public sales of equity. Our primary use of cash has been to support continuing operations and our investing activities, including capital expenditure requirements and acquisitions. As of June 30, 2013, and December 31, 2012, we had cash and cash equivalents of $300.3 million and $394.7 million, respectively. Cash and cash equivalents are primarily held in U.S. dollars and euros, other than those cash balances maintained in the local currency of subsidiaries to meet local working capital needs. At June 30, 2013, cash and cash equivalents had decreased by $94.4 million from December 31, 2012, primarily due to cash used in investing activities of $145.7 million and financing activities of $48.5 million, partially offset by cash provided by operating activities of $104.9 million. As of June 30, 2013 and December 31, 2012, we had working capital of $552.8 million and $683.7 million, respectively.

Operating Activities: For the six-months periods ended June 30, 2013 and 2012, we generated net cash from operating activities of $104.9 million and $107.5 million, respectively. While net loss was $56.9 million in the six-months ended June 30, 2013, non-cash components in income included $101.7 million of depreciation and amortization and $57.2 million of impairments. Operating cash flows include a net decrease in working capital of $7.4 million, primarily due to payments made in connection with restructuring activities, for which $4.9 million was accrued at December 31, 2012.

Because we rely heavily on cash generated from operating activities to fund our business, a decrease in demand for our products, longer collection cycles or significant technological advances of competitors would have a negative impact on our liquidity.

Investing Activities: Approximately $145.7 million of cash was used in investing activities during the six-months ended June 30, 2013, compared to $188.6 million for the same period in 2012. Investing activities during the six-months ended June 30, 2013 consisted principally of $33.7 million in cash paid for purchases of property and equipment, primarily in our ongoing construction projects in Germany and the U.S., as well as $15.7 million paid for intangible assets. Cash paid for acquisitions, net of cash acquired, of $102.4 million was primarily related to the Ingenuity acquisition.

In 2009 and 2010, we started the expansion of our Hilden, Germany, and Germantown, Maryland, USA facilities, respectively. While the construction in Germany complete, the U.S. expansion projects are expected to continue into 2014, with both projects being completed at an estimated total cost of approximately $94.0 million, of which $91.1 million was incurred as of June 30, 2013. We anticipate that we will be able to fund such expansions with cash generated by operating activities.

In connection with certain acquisitions, we could be required to make additional contingent cash payments totaling up to $129.0 million based on the achievement of certain revenue and operating results milestones as follows: $14.2 million in the remainder of 2013, $23.4 million in 2014, $16.2 million in 2015, $17.5 million in 2016, $7.0 million in 2017, and $50.7 million payable in any 12-month period from now until 2017 based on the accomplishment of certain revenue targets, the launch of certain products or the grant of certain patent rights. Of the $129.0 million total contingent obligation, we have assessed the fair value at June 30, 2013 to be $14.2 million, where $9.5 million and $4.7 million are included in other current liabilities and other non-current liabilities, respectively, as of June 30, 2013.

Financing Activities: Financing activities used $48.5 million in cash for the six-months ended June 30, 2013 compared to $74.3 million for the six-months ended June 30, 2012. Cash used during the six months ended June 30, 2013 was primarily for the purchase of treasury shares of $63.3 million partially offset by $18.1 million for the issuance of common shares in connection with our stock plan.

In December 31, 2011, we entered into a €400.0 million syndicated multi-currency revolving credit facility expiring December 2016 of which no amounts were utilized at June 30, 2013. The €400.0 million facility can be utilized in euro, U.K pound or U.S. dollar and bears interest of 0.8% to 2.35% above three months EURIBOR, or LIBOR in relation to any loan not in euro, and is offered with interest periods of one, two, three, six or twelve months. We have additional credit lines totaling €38.0 million at variable interest rates, of which no amounts were utilized as of June 30, 2013. We also have capital lease obligations, including interest, in the aggregate amount of $17.8 million, and carry $846.4 million of long-term debt, of which $0.7 million is current as of June 30, 2013.

In October 2012, we completed a U.S. private placement through the issuance of new senior unsecured notes at a total amount of $400 million with a weighted average interest rate of 3.66% (settled on October 16, 2012). The notes were issued in three series: (1) $73 million 7-year term due in 2019 (3.19%); (2) $300 million 10-year term due in 2022 (3.75%); and (3) $27 million 12-year term due in 2024 (3.90%). Approximately EUR 170 million (approximately $220 million) of proceeds from the notes were used to repay amounts outstanding under our short-term revolving credit facility. The remainder of the proceeds provides additional resources to support QIAGEN's longer-term business expansion.

In 2012, the Supervisory Board approved a program authorizing management to purchase up to a total of $100 million of our common shares (excluding transaction costs). In the first quarter of 2013, 3.1 million QIAGEN shares were repurchased for approximately $63.3 million. We completed the share repurchase program in April 2013 having repurchased between October 2012 and April 2013 a total of 5.1 million QIAGEN shares for a total of $99.0 million.

In July 2013, we announced our intention to exercise the authorization granted by the Annual General Meeting of Shareholders on June 26, 2013, to purchase up to $100 million of our common shares (excluding transaction costs). Based on the closing price on July 29, 2013, this represents approximately 5.0 million common shares. Details of the repurchase program will be announced before its actual commencement in line with Article 4, Section (2) of EC regulation 2273/2003 (so called Safe Harbor). Repurchased shares will be held in treasury in order to satisfy obligations for exchangeable debt instruments and employee share-based remuneration plans.

We expect that cash from financing activities will continue to be impacted by issuances of our common shares in connection with our equity compensation plans and that the market performance of our stock will impact the timing and volume of the issuances. Additionally, we may make future acquisitions or investments requiring cash payments, the issuance of additional equity or debt financing.

We believe that funds from operations, existing cash and cash equivalents, together with the proceeds from our public and private sales of equity, and availability of financing facilities, will be sufficient to fund our planned operations and expansion during the coming year. However, the global economic downturn may have a greater impact on our business than currently expected, and we may experience a decrease in the sales of our products, which could impact our ability to generate cash. The availability of debt financing may be negatively impacted by the global credit crisis. If our future cash flows from operations and other capital resources are not adequate to fund our liquidity needs, we may be required to obtain additional debt or equity financing or to reduce or delay our capital expenditures, acquisitions or research and development projects. If we cannot obtain financing on a timely basis or at satisfactory terms, or implement timely reductions in our expenditures, our business could be adversely affected.

Quantitative and Qualitative Disclosures about Market Risk

Our market risk relates primarily to interest rate exposures on cash, marketable securities and borrowings and foreign currency exposures on intercompany and third-party transactions. The overall objective of our risk management is to reduce the potential negative earnings effects from changes in interest and foreign currency exchange rates. Exposures are managed through operational methods and financial instruments. We do not use financial instruments for trading or speculative purposes. Our exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from our exposure as discussed in our Annual Report for the year ended December 31, 2012

Contractual Obligations

There were no material changes at June 30, 2013, from the contractual obligations disclosed in our Annual Report for the year ended December 31, 2012 other than an increase in purchase commitments connection with a new IT outsourcing agreement we entered into in 2013. Under these agreements we could be required to make additional payments up to $10.2 million in 2013, $8.2 million in 2014, $7.8 million in 2015, $7.0 million in 2016, $7.2 million in 2017 and $16.1 million thereafter.

Legal Proceedings

For information on legal proceedings, see Note 14 to the accompanying selected notes to the condensed consolidated financial statements.

While no assurances can be given regarding the outcome of the proceeding described in Note 14, based on information currently available, we believe that the resolution of these matters is unlikely to have a material adverse effect on our financial position or results of future operations for QIAGEN N.V. as a whole. However, because of the nature and inherent uncertainties of litigation, should the outcomes be unfavorable, certain aspects of our business, financial condition, and results of operations and cash flows could be materially adversely affected.

Principal risks and uncertainties

Our risk categories and risk factors which could have a material impact on our financial position and result are extensively described in QIAGEN's 2012 Annual Report. Those risk categories and factors are deemed incorporated and repeated in this report by this reference and we believe that these risks similarly apply for the last six-months of 2013. More information can be found under the Management Report of the 2012 Annual Report.

2013 Outlook

We are moving ahead, amid challenging market conditions, to accelerate the pace of innovation and growth in 2013. Building on the progress of strategic initiatives to leverage our leadership in Sample & Assay Technologies across all customer classes, goals for 2013 focus on continuing to drive platform success, add test content for use in all customer classes and broaden our geographic presence. Additional goals are to deliver efficiency and effectiveness through resource allocation, improve our position as an employer of choice and enhance customer experience. Based on the performance in the first half of the year, we continue to expect to deliver improved results in 2013. We expect adjusted net sales, excluding currency impacts, to grow approximately 5% in 2013, and adjusted diluted EPS for 2013 of approximately $1.13. For the third quarter of 2013, we expect adjusted net sales to grow approximately, excluding current impacts, with adjusted diluted EPS of approximately $0.27. These expectations reaffirm the previous guidance provided on April 29, 2013, and do not take into account any further acquisitions that could be completed in 2013.

Signatures

Venlo, August 2, 2013

QIAGEN N.V.

/s/ Peer M. Schatz	**/s/ Roland Sackers**
CEO	CFO